SLC3A2 and ovarian carcinoma: Overall, our data indicate that the axis of METTL5‐ATF4‐SLC7A11/SLC3A2 plays a vital role in promoting immune resistance in ovarian cancer models and patients, and targeting METTL5 could improve the effectiveness of immunotherapy in OC patients.